Quick Answer
Allarity Therapeutics, Inc. reported Cash and Equivalents of $14.69 million for fiscal year 2025.
Allarity Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.69M | -24.8% |
| 2024 | $19.53M | +11666.9% |
| 2023 | $166.0K | -91.8% |
| 2022 | $2.03M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $16.89M | — | -5.1% |
| June 30, 2025 | $17.80M | -7.4% | -29.4% |
| March 31, 2025 | $25.20M | +7977.2% | +29.0% |
| December 31, 2024 | $19.53M | +11666.9% | +1.6% |
| June 30, 2024 | $19.23M | +4479.3% | +6064.4% |
| March 31, 2024 | $312.0K | +5.8% | +88.0% |
| December 31, 2023 | $166.0K | — | -88.1% |
| September 30, 2023 | $1.40M | -64.5% | +233.1% |
- Allarity Therapeutics, Inc. showed a decrease of -24.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Allarity Therapeutics, Inc.’s cash and equivalents has grown by 623.9% (from $2.03 million to $14.69 million).
- The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: